Neumora Therapeutics (NMRA) Long-Term Debt Issuances (2025)
Neumora Therapeutics (NMRA) recorded quarterly Long-Term Debt Issuances of $38.9 million in Q4 2025, up 28702.21% quarter-over-quarter from -$136000.0 in Q3 2025.
Neumora Therapeutics (NMRA) Long-Term Debt Issuances (2025) Analysis & Trends
Neumora Therapeutics' Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $38.9 million for Q4 2025.
- In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $38.9 million; the TTM figure through Dec 2025 stood at $38.8 million (changed N/A YoY), while the FY2025 annual figure was $57.2 million, changed N/A from the prior year.
- Long-Term Debt Issuances was $38.9 million for Q4 2025 at Neumora Therapeutics, up from -$136000.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $38.9 million in Q4 2025 to a low of -$136000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 2.73 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Neumora Therapeutics | 320.17 Mn | 320.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 38.90 Mn |
| Dec 31, 2025 | 38.90 Mn |
| Sep 30, 2025 | -136,000.00 |
| Sep 30, 2025 | -136,000.00 |